Cargando…
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time...
Autores principales: | De Cock, Erwin, Kritikou, Persefoni, Sandoval, Mariana, Tao, Sunning, Wiesner, Christof, Carella, Angelo Michele, Ngoh, Charles, Waterboer, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928781/ https://www.ncbi.nlm.nih.gov/pubmed/27362533 http://dx.doi.org/10.1371/journal.pone.0157957 |
Ejemplares similares
-
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries
por: Body, Jean-Jacques, et al.
Publicado: (2017) -
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016) -
Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
por: Theodore-Oklota, Christina, et al.
Publicado: (2016) -
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019) -
Rituximab-Induced Interstitial Lung Disease: A Stitch in Time Saved Nine
por: Tej, Sai, et al.
Publicado: (2022)